174 related articles for article (PubMed ID: 10901181)
1. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
[TBL] [Abstract][Full Text] [Related]
2. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia.
Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
Ren Fail; 2000 Mar; 22(2):205-11. PubMed ID: 10803764
[TBL] [Abstract][Full Text] [Related]
3. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease.
Berns JS; Rudnick MR; Cohen RM; Bower JD; Wood BC
Kidney Int; 1999 Jul; 56(1):253-60. PubMed ID: 10411700
[TBL] [Abstract][Full Text] [Related]
4. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
Azmandian J; Abbasi MR; Pourfarziani V; Nasiri AA; Ossareh S; Ezzatzadegan Jahromi S; Sanadgol H; Amini S; Shahvaroughi Farahani A
Am J Nephrol; 2018; 48(4):251-259. PubMed ID: 30253403
[TBL] [Abstract][Full Text] [Related]
5. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
6. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
Kilpatrick RD; Critchlow CW; Fishbane S; Besarab A; Stehman-Breen C; Krishnan M; Bradbury BD
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1077-83. PubMed ID: 18417744
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
[TBL] [Abstract][Full Text] [Related]
8. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
9. The effect of epoetin dose on hematocrit.
Cotter D; Zhang Y; Thamer M; Kaufman J; Hernán MA
Kidney Int; 2008 Feb; 73(3):347-53. PubMed ID: 18004296
[TBL] [Abstract][Full Text] [Related]
10. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
11. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
12. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
[TBL] [Abstract][Full Text] [Related]
13. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study.
Bren A; Kandus A; Varl J; Buturović J; Ponikvar R; Kveder R; Primozic S; Ivanovich P
Artif Organs; 2002 Feb; 26(2):91-7. PubMed ID: 11879235
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
15. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients.
Johnson CA; Wakeen M; Taylor CA; Zimmerman SW; Burkart J; Bhattacharya A; Kosorok MR
Perit Dial Int; 1999; 19(6):578-82. PubMed ID: 10641779
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
[TBL] [Abstract][Full Text] [Related]
19. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
20. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
